- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main Inclusion Criteria:
The subject has one of the following confirmed diseases that is refractory to or relapsed from established therapies. Note: A subject with one of these disease who is intolerant (as defined in the protocol) to established therapies is also allowed:
- Acute myelogenous leukemia
- Acute lymphoblastic leukemia
- Chronic myelogenous leukemia (CML) (chronic phase, accelerated phase, or blast crisis)
- Chronic lymphocytic leukemia
- Multiple myeloma
- Waldenstrom's macroglobulinemia
- Intermediate or high risk myelodysplastic syndrome
One of the following myeloproliferative disorders:
- Philadelphia chromosome-negative CML (including blast phase).
- All subtypes of myeloid metaplasia with myelofibrosis.
- Advanced polycythemia vera in the spent phase (ie, presence of anemia).
- Non-Hodgkins lymphoma
- The interval between the last prior treatment and the start of study drug administration is at least 30 days for radiotherapy, at least 14 days for cytotoxic chemotherapy (42 days for nitrosureas or mitomycin C), and at least 5 half-lives for noncytotoxic agents. The only exception is hydroxyurea, which can be used prior to starting study drug and during Cycle 1, as defined in the protocol.
- For subjects with prior autologous bone marrow or peripheral blood stem cell transplantation, the interval between transplant and the start of study drug administration is at least 30 days.
- For subjects with prior allogeneic bone marrow or peripheral blood stem cell transplantation, the interval between transplant and the start of study drug administration is at least 90 days.
- If taking steroids chronically, the subject has been receiving a stable steroid dose for at least 21 days prior to the start of study drug administration, and the daily steroid dose does not exceed the equivalent of 20 mg prednisone.
- The subject is aged 18 years or older.
- The subject weighs at least 45 kg.
- The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
- The subject has adequate liver and kidney function.
- The subject has adequate heart function (left ventricular ejection fraction ≥ 50%).
Main Exclusion Criteria:
Any subject who meets any of the following criteria will not qualify for entry into the study:
- The subject has a platelet count (untransfused) < 50,000/mm3 and/or an absolute neutrophil count < 1000/mm3 that is not caused by the underlying disease infiltrating the bone marrow.
- The subject has evidence of active malignancy in the central nervous system (CNS)or has had CNS involvement documented within the past 90 days. Subjects who are receiving maintenance intrathecal chemotherapy for previous CNS involvement but have no current evidence of disease are allowed if the CNS involvement was documented more than 90 days ago.
- The subject has any evidence of acute or chronic graft versus host disease.
- The subject has a history of hypersensitivity or allergic reactions attributed to compounds of similar chemical composition to TAK-901 or its excipient, Captisol.
- The subject is pregnant or lactating.
- The subject has had a myocardial infarction, cerebrovascular accident, transient ischemic attack, clinically significant ventricular arrhythmia, or pulmonary embolus within 6 months prior to the start of study drug administration.
- The subject's electrocardiogram demonstrates an abnormal QT interval , as defined by the protocol.
- The subject requires dialysis.
- The subject is on systemic anticoagulation therapy.
- The subject has an uncontrolled intercurrent illness as defined in the protocol.
- The subject is known to have human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.
- The subject has a currently active second malignancy other than nonmelanoma skin cancer or in situ carcinoma of the cervix. A malignancy is considered to be currently active if the subject is receiving ongoing therapy or has been in remission for less than 2 years prior to the first dose of study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
TAK-901
|
TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the maximum tolerated dose(MTD)of TAK-901 in subjects with advanced hematologic malignancies.
Time Frame: Duration of the study
|
Duration of the study
|
To further assess the safety and tolerability of TAK-901 at or below the MTD in an expanded cohort of subjects in order to select a dose for future studies.
Time Frame: Duration of study
|
Duration of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the pharmacokinetic profile of TAK-901 and its primary metabolite (M-I).
Time Frame: Duration of the study
|
Duration of the study
|
To make a preliminary assessment of the clinical activity of TAK-901.
Time Frame: Duration of therapy
|
Duration of therapy
|
To make a preliminary assessment of the effects of TAK-901 on pharmacodynamic biomarkers.
Time Frame: Duration of therapy
|
Duration of therapy
|
To make a preliminary assessment of the association between selected genetic markers and TAK-901 response and/or pharmacokinetic parameters.
Time Frame: Duration of therapy
|
Duration of therapy
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Myeloproliferative Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Precancerous Conditions
- Leukemia, Lymphoid
- Leukemia, B-Cell
- Chromosome Aberrations
- Translocation, Genetic
- Myelodysplastic Syndromes
- Hematologic Neoplasms
- Primary Myelofibrosis
- Multiple Myeloma
- Leukemia
- Leukemia, Myeloid
- Preleukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Waldenstrom Macroglobulinemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Philadelphia Chromosome
- Polycythemia
- Metaplasia
Other Study ID Numbers
- TAK-901_101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Uma BorateNot yet recruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 MutationUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
Clinical Trials on TAK-901
-
Millennium Pharmaceuticals, Inc.CompletedLymphoma | Advanced Solid TumorsUnited States
-
Stemline Therapeutics, Inc.CompletedStudy of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid TumorsAdvanced Solid TumorUnited Kingdom
-
ADC Therapeutics S.A.Active, not recruitingAdvanced Solid TumorsUnited States, Spain, United Kingdom
-
Urovant Sciences GmbHCompletedOveractive BladderUnited States, Spain, Canada, Portugal, Poland, Belgium, Hungary, Lithuania
-
Urovant Sciences GmbHCompletedIrritable Bowel SyndromeUnited States
-
Urovant Sciences GmbHCompletedOveractive BladderUnited States, Poland
-
Reata, a wholly owned subsidiary of BiogenRecruitingA Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS)Diabetic Peripheral Neuropathic PainUnited States
-
Aerami TherapeuticsCompletedPulmonary Arterial HypertensionAustralia
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Dartmouth-Hitchcock Medical CenterMuhimbili University of Health and Allied SciencesCompleted